Sonendo, Inc. is a medical technology company that focuses on advancing dental care through innovative devices for root canal therapy. Based in Laguna Hills, California, Sonendo has developed the GentleWave® System, which enhances the cleaning and disinfection of tooth canals, improving clinical outcomes and efficiency compared to traditional methods. The company operates primarily through two segments: the Product segment, which includes sales of the GentleWave System and its related instruments, and the Software segment, which encompasses TDO® Software—widely recognized as a leading practice management solution for endodontics. Since its incorporation in 2006, Sonendo has aimed to transform dentistry by promoting effective treatments that preserve tooth structure and enhance patient care.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.
Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapies for cancer treatment. Based in New Haven, Connecticut, the company employs directed evolution to create novel cytokines aimed at enhancing the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor activity in animal studies, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. Founded in 2018, Simcha Therapeutics is dedicated to advancing innovative therapies that empower patients to effectively fight cancer.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
Fyllo Inc. is a marketing technology company that specializes in serving the cannabis industry. Founded in 2019 and headquartered in Chicago, Illinois, with additional offices in major cities across North America and Israel, Fyllo offers a comprehensive platform designed to address the unique challenges of this highly regulated market. The Fyllo Compliance Cloud provides enterprise-grade software and services, leveraging RegsTechnology's extensive database of cannabis laws and regulations at various governmental levels. Fyllo's solutions encompass data analytics, ad campaign management, measurement and reporting, and creative management services, enabling marketers and legal professionals to navigate compliance complexities while driving growth and engagement.
SmartLabs specializes in designing, building, and operating integrated research environments tailored for the scientific community. The company provides multifunctional facilities that encompass research and development labs, vivariums, process development suites, pilot-scale manufacturing, and cGMP suites. By offering these full-service laboratory spaces, SmartLabs aims to enhance the pace of scientific discovery and facilitate the development of effective therapeutics. Their facilities are suitable for companies of all sizes, enabling medical professionals to streamline their research processes and bring innovative solutions to market more efficiently.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.
Tvardi Therapeutics, Inc. is a biotechnology company that specializes in developing innovative treatments for cancer, chronic inflammation, and fibrosis. The company's primary focus is on inhibitors of STAT3, a regulatory protein that plays a crucial role in various signaling pathways related to cancer cell survival and immune response. Tvardi's product pipeline includes TTI-101, an oral small-molecule inhibitor of STAT3, and its intravenous formulation for non-cancer indications, as well as TTI-102, another oral candidate that targets STAT3. Founded in 2017 and based in Houston, Texas, Tvardi Therapeutics aims to provide effective therapies for conditions such as breast and lung cancer, addressing significant medical needs in oncology and inflammatory diseases.
Tvardi Therapeutics, Inc. is a biotechnology company that specializes in developing innovative treatments for cancer, chronic inflammation, and fibrosis. The company's primary focus is on inhibitors of STAT3, a regulatory protein that plays a crucial role in various signaling pathways related to cancer cell survival and immune response. Tvardi's product pipeline includes TTI-101, an oral small-molecule inhibitor of STAT3, and its intravenous formulation for non-cancer indications, as well as TTI-102, another oral candidate that targets STAT3. Founded in 2017 and based in Houston, Texas, Tvardi Therapeutics aims to provide effective therapies for conditions such as breast and lung cancer, addressing significant medical needs in oncology and inflammatory diseases.
Latch is a New York-based company that enhances access management for modern buildings through its innovative keyless entry security systems. The company offers a comprehensive solution that allows property owners to manage all doors within multi-family buildings via a smartphone application. This system also enables residents to grant time-limited access to guests and service providers, improving convenience and security. LatchOS, the software platform developed by the company, operates across North America, serving diverse environments from affordable housing to luxury residential towers. Latch collaborates with a range of real estate developers, from large corporations to local property owners, to improve the living, working, and visiting experiences in various types of buildings.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.
Adagio Medical specializes in the design and manufacture of medical devices aimed at treating cardiac arrhythmias. Founded in 2011 and based in Laguna Hills, California, the company is dedicated to the research and development of innovative cryoablation catheters. These devices are engineered to create safe, continuous, transmural lesions that effectively address various cardiac conditions, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. Adagio Medical's product offerings include the continuous lesion ablation system (iCLAS), specialized catheters, esophageal balloons, and consoles, all developed to enhance the capabilities of electrophysiologists in the treatment of cardiovascular diseases.
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.
Shift Technologies, Inc. operates an online platform that facilitates the buying and selling of new and used cars, offering a range of vehicle types including sedans, SUVs, and trucks. Founded in 2013 and headquartered in San Francisco, California, with additional locations in Los Angeles, San Diego, Sacramento, and Portland, Shift aims to simplify the car purchase experience. The company provides a comprehensive service that includes detailing vehicles, listing them on multiple platforms, managing test drives, and connecting sellers with potential buyers. Customers receive a detailed 150-point concierge report that encompasses vehicle specifications, high-resolution images, and history reports. Shift also offers financing options and additional support services throughout the car ownership lifecycle, making the process more accessible and enjoyable for consumers.
Xometry Inc. is a provider of on-demand manufacturing services based in Gaithersburg, Maryland, founded in 2013. The company operates an online marketplace that connects customers with a network of machine shops and custom manufacturers, allowing for efficient sourcing of high-quality parts. Xometry's capabilities include CNC machining, 3D printing, injection molding, urethane casting, and die casting, among others. The company employs proprietary technology to deliver optimal pricing for various manufacturing solutions, facilitating rapid prototyping and volume production. Its clientele includes notable organizations such as Toyota, NASA, Caterpillar, and Medtronic. Xometry aims to enhance domestic manufacturing by leveraging software that streamlines the process of obtaining custom parts. The company has a strategic partnership with Roush Yates Manufacturing Solutions and serves a diverse range of customers, including engineers, product designers, and business owners.
Evolve Vacation Rental Network, Inc. operates a marketing and booking platform that offers vacation rental management services for both guests and homeowners. Founded in 2010 and based in Denver, Colorado, the company allows homeowners to effectively market and manage their vacation properties online. Evolve provides a range of services, including professional property listings, marketing, guest communications, and local service provider information. By leveraging a network of vetted local partners, Evolve ensures that essential services such as housekeeping and maintenance are efficiently handled. This approach enables homeowners to achieve higher rental income at reduced costs compared to traditional property management options, while also enhancing the travel experience for guests.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
SmartLabs specializes in designing, building, and operating integrated research environments tailored for the scientific community. The company provides multifunctional facilities that encompass research and development labs, vivariums, process development suites, pilot-scale manufacturing, and cGMP suites. By offering these full-service laboratory spaces, SmartLabs aims to enhance the pace of scientific discovery and facilitate the development of effective therapeutics. Their facilities are suitable for companies of all sizes, enabling medical professionals to streamline their research processes and bring innovative solutions to market more efficiently.
ArcherDX, Inc. is a genomics company based in Boulder, Colorado, focused on advancing molecular pathology through next-generation sequencing technology. Established in 2013, the company develops and commercializes a range of research products, including DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex, and RNA-based Immunoverse, aimed at optimizing therapy and monitoring cancer. ArcherDX also creates in-vitro diagnostic products and offers customizable assay design services to clinical and biopharmaceutical clients, enabling the development of new applications tailored to specific biomarker targets. The Archer platform utilizes proprietary Anchored Multiplexed PCR (AMP™) chemistry and sophisticated bioinformatics to enhance genetic mutation detection significantly. The company's products and services are utilized by academic and reference laboratories, biopharmaceutical firms, and contract research organizations, with ongoing efforts to gain regulatory approval for various companion diagnostic assays. As of October 2020, ArcherDX operates as a subsidiary of Invitae Corporation.
Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.
Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company is focused on addressing complex disease biology through its proprietary protein engineering methods, including a single-domain antibody platform. Its key candidates include INBRX-109, a multivalent agonist targeting death receptor 5 for solid tumors; INBRX-105, an antagonist of PD-L1 and conditional agonist of 4-1BB for PD-L1 expressing tumors; INBRX-101, an Fc-fusion protein aimed at alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting cluster of differentiation 47. Additionally, Inhibrx has preclinical programs such as INBRX-106 and INBRX-111, which focus on oncology and infectious diseases. The company has established collaborations with organizations like Celgene and bluebird bio and has received support from various granting agencies, including the NIH and CARB-X.
Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for underserved patient populations affected by rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company’s lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III trials for treating desmoid tumors. Other significant candidates include mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for relapsed or refractory multiple myeloma. The company is also exploring additional therapies, such as BGB-3245, an investigational oral inhibitor targeting BRAF mutations, currently in Phase I trials. SpringWorks has established collaborations with several biotechnology and pharmaceutical firms to enhance its research and development efforts.
Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
Evolve Vacation Rental Network, Inc. operates a marketing and booking platform that offers vacation rental management services for both guests and homeowners. Founded in 2010 and based in Denver, Colorado, the company allows homeowners to effectively market and manage their vacation properties online. Evolve provides a range of services, including professional property listings, marketing, guest communications, and local service provider information. By leveraging a network of vetted local partners, Evolve ensures that essential services such as housekeeping and maintenance are efficiently handled. This approach enables homeowners to achieve higher rental income at reduced costs compared to traditional property management options, while also enhancing the travel experience for guests.
Convene designs and services premium places to work, meet, and host inspiring events. Through strategic partnerships with prominent commercial landlords, Convene operates a network of hospitality-driven locations in Class A office buildings across major U.S. cities, with plans to expand globally. Convene has raised $260M in equity funding to date, and has been named one of America’s 100 Most Promising Companies by Forbes and a Best Workplace by both Inc. and Fortune Magazine.
Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for retinal diseases. The company's leading candidate, KSI-301, is a vascular endothelial growth factor (VEGF)-biological agent currently undergoing Phase 1b clinical trials for the treatment of wet age-related macular degeneration and diabetic retinopathy. Additionally, Kodiak is advancing KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate aimed at addressing inflammation and abnormal blood vessel growth associated with retinal vascular diseases, which is in the preclinical stage. The company's early research pipeline also includes KSI-601, a triplet inhibitor targeting dry AMD. Founded in 2009 and headquartered in Palo Alto, California, Kodiak Sciences was previously known as Oligasis, LLC before its name change in 2015.
Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. It has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. It has three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action.
The company's portfolio of product candidates offers multiple development opportunities. By modulating different parts of the innate and adaptive immune system, these product candidates together have the potential to provide a variety of mechanisms to address multiple devastating diseases.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.
Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company dedicated to developing novel, non-opioid, and non-addictive therapies for chronic pain management. Founded in 2013 and based in Boston, Massachusetts, the company’s product pipeline includes CNTX-4975, currently undergoing Phase III trials for knee osteoarthritis pain and Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials for various chronic pain conditions, while CNTX-6970 targets inflammatory pain and CNTX-2022, a high-concentration topical gel formulation of lidocaine, is also in Phase I trials for superficial musculoskeletal pain and related conditions. Furthermore, CNTX-6016 is a pre-clinical candidate aimed at treating chronic neuropathic pain. Centrexion Therapeutics is committed to addressing the unmet medical needs in chronic pain treatment by focusing on safety and efficacy.
NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, that specializes in developing innovative immuno-therapeutics using its proprietary Artificial Immune (AIM) technology. Founded in 2011, the company focuses on orchestrating specific immune responses to treat various conditions, including cancer, inflammation, viral diseases, transplant rejection, and autoimmunity. NexImmune's lead products include AIM101, an injectable therapy targeting specific solid tumors, and AIM ACT, an adoptive cellular therapy aimed at treating specific hematological malignancies. The company is currently advancing two product candidates in clinical trials: NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma, both designed to harness the body's T cells for a targeted immune response with potential curative effects.
Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.
Our mission is to improve daily life in cities and public spaces. At Intersection, we are at the forefront of the smart cities revolution. With award-winning products like Link, the largest and fastest free public Wi-Fi network in the world, Intersection connects the digital and physical worlds, enhancing people’s journeys through their cities and offering brands the opportunity to drive more relevant and engaging advertising, rooted in real-world location and physical context. We believe that by joining the digital and physical worlds we can help people get the most out of the cities around them. Our products live in public locations, where people engage with them every day, delivering connectivity, information, and content that elevate the urban experience. Intersection was formed from the merger between Titan, the largest municipal out-of-home advertising company, and Control Group, a leader in technology and design innovation in physical spaces. Together, these companies created a unique and powerful combination of expertise in cities, media, technology, and design, with scale, experience, and resources to connect the digital and physical worlds as never before. The first product of that collaboration was LinkNYC—widely recognized as among the most successful smart city technologies on the planet. And we’re just getting started…
Convene designs and services premium places to work, meet, and host inspiring events. Through strategic partnerships with prominent commercial landlords, Convene operates a network of hospitality-driven locations in Class A office buildings across major U.S. cities, with plans to expand globally. Convene has raised $260M in equity funding to date, and has been named one of America’s 100 Most Promising Companies by Forbes and a Best Workplace by both Inc. and Fortune Magazine.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Convene designs and services premium places to work, meet, and host inspiring events. Through strategic partnerships with prominent commercial landlords, Convene operates a network of hospitality-driven locations in Class A office buildings across major U.S. cities, with plans to expand globally. Convene has raised $260M in equity funding to date, and has been named one of America’s 100 Most Promising Companies by Forbes and a Best Workplace by both Inc. and Fortune Magazine.
Twilio is a cloud communications platform that enables developers and businesses to integrate voice, video, messaging, and authentication features into their applications. Founded in 2008 and based in San Francisco, Twilio offers a range of application programming interfaces (APIs) and prebuilt solutions to enhance customer engagement experiences. The platform supports the creation of voice, VoIP, and SMS applications, allowing users to build customized communication tools. By leveraging a global network of carrier relationships, known as the Super Network, Twilio facilitates efficient and cost-effective communication, thereby reinventing the telecom landscape. Additionally, Twilio has established funds to support startups in Europe that utilize its cloud communication services to develop innovative business solutions.
MarkLogic Corporation is an enterprise software company that specializes in providing technology solutions to simplify data integration for organizations globally. Its primary offering is an Enterprise NoSQL database that facilitates various applications, including client onboarding, content management, data unification, and digital asset management. The MarkLogic Data Hub Service allows businesses to integrate, store, analyze, and secure mission-critical data in the cloud, supporting sectors such as finance, healthcare, media, and government. The platform is designed to eliminate friction in the data integration process, enabling organizations to achieve comprehensive data visibility and agility while reducing IT costs. MarkLogic serves a diverse clientele, including major banks, pharmaceutical companies, and government agencies, and operates from its headquarters in San Carlos, California, with additional offices worldwide. Founded in 2001, the company has established strategic partnerships with various technology firms to enhance its service offerings.
Sapphire Energy, Inc. is a San Diego-based company specializing in the production of renewable solutions from algae, aiming to innovate the energy and petrochemical industries through its Green Crude initiative. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, non-arable land, and specific strains of algae in outdoor ponds to generate biomass. This biomass can be transformed into high-value products, including oils, aquaculture and animal feeds, and fuels. Unlike traditional biofuels, Sapphire's processes are not reliant on food crops or valuable farmland, do not consume potable water, and yield products compatible with existing infrastructure. The company operates a research and development facility in Las Cruces, New Mexico, and is developing an integrated algal bio refinery in Columbus, New Mexico, to enhance its production capabilities.